XBiotech Inc. — Q1 2022 Form 10-Q
Business context and reporting period. XBiotech is a pre-commercial biopharmaceutical company developing naturally occurring “True Human” antibody therapies. This unaudited report covers the three months ended March 31, 2022; comparisons are with Q1 2021 unless otherwise noted. The company is developing multiple IL-1α-targeting candidates, including a candidate in an oncology clinical study. It also manufactures bermekimab for Janssen clinical trials under an agreement extended through December 2023.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | $0.5 million | $4.85 million; down about 90% |
| Gross profit / margin | $0.287 million / 57.4% | $2.546 million / 52.5% |
| Research and development | $6.818 million | $4.634 million; up 47% |
| General and administrative | $1.314 million | $1.465 million; down 10% |
| Operating loss | $7.845 million | $3.553 million |
| Net loss / loss per share | $5.395 million / $0.18 | $2.568 million / $0.09 |
| Operating cash flow | $(5.123) million | $1.809 million provided |
| Cash and cash equivalents | $231.821 million at March 31, 2022 | $236.983 million at December 31, 2021 |
Amounts are in U.S. dollars. The Q1 2022 net loss included $1.290 million of foreign-exchange gain and a $1.059 million income-tax benefit. Comprehensive loss was $5.273 million. Cash used in investing was $0.161 million; financing cash flow was nil. Total liabilities were $5.243 million, including $1.479 million of long-term income tax payable and $0.873 million of deferred tax liability. The balance sheet reports no borrowings or other interest-bearing debt.
Material changes and management commentary
- Revenue fell primarily because the prior-year quarter included $4.5 million of manufacturing revenue and $0.35 million of clinical-trial service revenue. The new Janssen-related manufacturing arrangement generated $0.5 million in Q1 2022 and may generate up to $4.7 million through December 2023.
- R&D expense increased by $2.184 million. Management attributed the change mainly to expense classification differences and higher share-based compensation following employee grants in Q4 2021. R&D costs are not tracked by individual candidate.
- Operating cash flow shifted from a $1.809 million inflow to a $5.123 million outflow, which management primarily attributed to Janssen revenue in Q1 2021.
- Management expects operating losses to continue and increase as candidates advance; it also anticipates higher G&A costs, citing inflationary trends. The company stated that its cash should fund operations for at least 12 months from the report date and support several potential clinical inflection points.
- The company expects no further revenue under the manufacturing agreement after December 2023. It says future profitability depends on successfully commercializing product candidates and may never be achieved.
Risks, contingencies, and unusual items
- Key risks include clinical and regulatory uncertainty, trial timing and cost, patient recruitment, competition, intellectual-property protection, commercialization, and the need for future financing. The filing reports no material changes to the risk factors in the 2021 Form 10-K.
- Foreign-exchange gains were materially higher year over year and were attributed mainly to U.S.-dollar/Canadian-dollar movements. The company reports no hedging activities and no material market risk exposure.
- Deferred tax assets are subject to valuation allowances in the U.S. and Germany and for certain Canadian amounts. Unrecognized tax benefits were reported at $2.4 million at December 31, 2021, with a $14,000 increase in accrued interest during Q1 2022.
- The income-tax note contains an apparent drafting comment questioning the clarity of its effective-tax-rate disclosure. Investors should verify the intended explanation; the filing reports a Q1 tax benefit of $1.059 million and a consolidated effective tax rate of 16.41%.
- Management concluded disclosure controls were effective; it reported no material quarterly change in internal control over financial reporting. No off-balance-sheet arrangements were reported.
Most important facts for investors to verify
- Expected spending, trial milestones, and cash runway against the $231.8 million cash balance and ongoing operating losses.
- The timing and economics of the Janssen manufacturing revenue through December 2023, and the revenue sources expected afterward.
- Clinical progress and regulatory plans for lead candidates, including the IL-1α oncology program.
- The tax-rate disclosure and the treatment and recoverability of tax assets and uncertain tax positions.
- How much of the reported net loss and period-to-period change reflects foreign-exchange movements and share-based compensation.